Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) Рисунки

115 иллюстрации из рецензируемых исследований

Все Vitamin E Green Tea Extract (EGCG) Citicoline Folate Zinc Bacopa monnieri Omega-3 Fatty Acids (DHA/EPA) Alpha-Lipoic Acid Creatine Resveratrol Vitamin D L-Theanine Vitamin B12 Ginkgo biloba Lutein & Zeaxanthin Melatonin Rhodiola rosea Panax Ginseng Phosphatidylserine Taurine Curcumin Uridine Monophosphate
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 5
Figure 5

Alopecia and platelet-derived therapies.

Before
Figure 6

Before

Alopecia and platelet-derived therapies.

Figure 1: Step-by-step flow diagram of preparation of platelet-rich plasma using open double-spin method
Figure 1

Figure 1: Step-by-step flow diagram of preparation of platelet-rich plasma using open double-spin method

Platelet-Rich Plasma in Androgenetic Alopecia.

Fig. 1. Regional (A) R2, (B) R2*, (C) R2′ and (D) QSM values corrected for age and volume for healthy controls (blue) and RLS patients (red). CAU: Caudate, DEN: Dentate nuclei, PAL: Pallidum, PUT: Putamen, RN: Red nuclei, SN: Substantia Nigra, STN: Subtha
Figure 3

Fig. 1. Regional (A) R2, (B) R2*, (C) R2′ and (D) QSM values corrected for age and volume for healthy controls (blue) and RLS patients (red). CAU: Caudate, DEN: Dentate …

Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.

Fig. 2. Flow Diagram of the systematic search for MRI studies of iron in RLS.
Figure 4

Fig. 2. Flow Diagram of the systematic search for MRI studies of iron in RLS.

Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.

Figure 5
Figure 5

Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.

Figure 1
Figure 1

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies …

Figure 3
Figure 3

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies …

Figure 4
Figure 4

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies …

Figure 5
Figure 5

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies …

Figure 1. Experimental design. SCS: sodium carboxymethyl cellulose; BE: berberine and evodiamine; FF: fenofibrate.
Figure 5 Flowchart

The experimental design outlines the group allocation including sodium carboxymethyl cellulose control, berberine-evodiamine combination, and fenofibrate positive control arms.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver …

Figure 6
Figure 6 Chart

Gut microbiota composition analyzed by 16S rRNA sequencing reveals distinct community structures across treatment groups, with the combination therapy restoring microbial diversity.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver …

Figure 7
Figure 7 Chart

Alpha diversity indices of gut microbiota are compared across groups, indicating that berberine and evodiamine co-administration partially reverses high-fat diet-induced dysbiosis.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver …

Figure 8
Figure 8 Chart

Key bacterial taxa differentially abundant between treatment groups are identified, with specific genera associated with improved metabolic outcomes in the combination therapy arm.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver …

Figure 9
Figure 9 Chart

Short-chain fatty acid concentrations in fecal samples reflect changes in microbial metabolic activity following berberine and evodiamine treatment.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver …

Figure 10
Figure 10 Chart

Correlation analysis between gut microbiota composition and hepatic lipid parameters links specific bacterial taxa to the amelioration of non-alcoholic fatty liver disease.

The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver …

Figure 6
Figure 6 Chart

Blood levels of DHA, EPA, and arachidonic acid are tracked over the intervention period, confirming adherence and bioavailability of the fatty acid supplement.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 7
Figure 7 Chart

Plasma lutein and zeaxanthin concentrations are compared between treatment and control groups, demonstrating successful supplementation and absorption.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 8
Figure 8 Chart

Macular pigment optical density measurements assess the accumulation of lutein and zeaxanthin in the retina following supplementation.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 9
Figure 9 Chart

Verbal memory test performance including word recall and recognition tasks is compared between supplementation and placebo groups.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 10
Figure 10 Chart

Visual memory and spatial recall scores are assessed following LCPUFA and lutein/zeaxanthin supplementation compared to placebo.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 11
Figure 11 Chart

Working memory and executive function task results are presented for both treatment arms, assessing broader cognitive effects of the combined supplementation.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 12
Figure 12 Chart

Processing speed assessments compare reaction time and cognitive throughput between the supplemented and placebo groups.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Figure 13
Figure 13 Chart

Subgroup analyses stratify cognitive outcomes by baseline DHA status, revealing whether individuals with lower initial omega-3 levels benefit more from supplementation.

Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin …

Страница 3 из 5